Literature DB >> 26541980

Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.

Amanika Kumar1, Jo Marie Janco1, Andrea Mariani1, Jamie N Bakkum-Gamez1, Carrie L Langstraat1, Amy L Weaver2, Michaela E McGree2, William A Cliby3.   

Abstract

OBJECTIVES: To refine models to predict surgical morbidity and 90-day mortality after primary debulking surgery (PDS) for advanced epithelial ovarian cancer (EOC).
METHODS: Women with stage IIIC/IV EOC who underwent PDS with curative intent between 1/2/2003 and 12/30/2011 were included. Patient characteristics, intraoperative and postoperative outcomes, and vital status were abstracted. Complications were graded using the Accordion classification. Nomograms were generated based on multivariate modeling.
RESULTS: 138 (22.3%) of the 620 patients who underwent PDS experienced a grade≥3 complication. Age (OR 1.21 per 10 years increase in age), BMI (OR 1.35 for BMI<25 kg/m2 versus reference, OR 2.83 for BMI≥40 kg/m2 versus reference), ASA score≥3 (OR 1.49), stage (OR 1.69 stage IV) and surgical complexity (OR 2.32 high complexity versus intermediate) were predictive of an accordion grade≥3 complication Within 90 days of surgery, 55 (8.9%) patients died. A multivariable model included age (OR 1.76 per 10 year increase in age), ASA score≥3 (OR 3.28), preoperative albumin<3.5 (OR 4.31), and BMI (OR 2.04 for BMI<25 kg/m2 versus reference, OR 3.64 for BMI≥ 40 kg/m2 versus reference) was predictive of 90-day mortality.
CONCLUSION: Using an independent cohort we report the importance of age, ASA score, preoperative albumin, FIGO stage, and surgical complexity, and BMI, to refine a prediction model for complications after PDS for advanced EOC. This information is useful in preoperative counseling and can be utilized to aid in patient-centered decision making and risk stratification.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ovarian cancer; Surgical morbidity; Surgical mortality overall survival

Mesh:

Year:  2015        PMID: 26541980     DOI: 10.1016/j.ygyno.2015.10.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

1.  Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.

Authors:  Stephanie Cham; Ling Chen; Caryn M St Clair; June Y Hou; Ana I Tergas; Alexander Melamed; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2019-02-13       Impact factor: 8.661

2.  Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Authors:  Diogo Torres; Chen Wang; Amanika Kumar; Jamie N Bakkum-Gamez; Amy L Weaver; Michaela E McGree; Gottfried E Konecny; Ellen L Goode; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

3.  Accordion: A Useful and Workable Classification of Complications After Breast Reconstructive Surgery.

Authors:  Justyna Jończyk; Jerzy Jankau
Journal:  Plast Surg (Oakv)       Date:  2021-05-12       Impact factor: 0.558

4.  Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.

Authors:  Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Christa D Niehot; Heleen J van Beekhuizen
Journal:  J Gynecol Oncol       Date:  2022-06-07       Impact factor: 4.756

5.  Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.

Authors:  Deepa Maheswari Narasimhulu; Amanika Kumar; Amy L Weaver; Carrie L Langstraat; William A Cliby
Journal:  Gynecol Oncol       Date:  2020-04-01       Impact factor: 5.482

6.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

7.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

8.  The Influence of the Preoperative Status on the Risk of Postoperative Complications After Cytoreductive Surgery for Advanced-stage Ovarian Cancer.

Authors:  Laura Iliescu; Camelia Diaconu; Nicolae Bacalbasa; Irina Balescu; Mihai Dimitriu; Simona Dima; Mihaela Vilcu; Iulian Brezean
Journal:  In Vivo       Date:  2020 Mar-Apr       Impact factor: 2.155

9.  Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events.

Authors:  Alli M Straubhar; Jennifer L Wolf; Ms Qin C Zhou; Alexia Iasonos; Stephanie Cham; Jason D Wright; Kara Long Roche; Dennis S Chi; Oliver Zivanovic
Journal:  Gynecol Oncol       Date:  2020-12-04       Impact factor: 5.482

10.  Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.

Authors:  Deepa M Narasimhulu; Aneesa Thannickal; Amanika Kumar; Amy L Weaver; Michaela E McGree; Carrie L Langstraat; William A Cliby
Journal:  Gynecol Oncol       Date:  2020-12-31       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.